FMW Media’s “New To The Street” Syndicated TV Show Features AzurRx BioPharma, Inc.
May 14 2021 - 2:45PM
FMW Media Corp. announces that its “New To The Street” business TV
show will feature AzurRx BioPharma, Inc. (NASDAQ: AZRX) in a 3-part
TV series featured across its entire syndicated linear television
platform.
The televised interviews of with Mr. James
Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc.,
along with the “New To The Street’s” host Jane King, are to be
broadcasted on syndicated Newsmax Television, Sunday mornings
10-11AM ET. Also, the TV interview is being broadcasted on FOX
Business Network on Monday, May 17, 2021 at 10:30 PM PT. Future
filmed tapes and broadcasting on KRON-TV, RNN, Bloomberg TV and
other stations “To Be Announced.”
Mr. James Sapirstein, Chairman & CEO
of AzurRx BioPharma (NASDAQ: AZRX) talks to the “New To
The Street’s” TV audience about AZRX’s biopharmaceutical products
and therapies. He gives a comprehensive overview in the development
of targeted, non-systemic therapies for gastrointestinal (GI)
diseases. And, provides insight on its FDA Phase 2 clinical trials
on its lead therapeutic candidate MS1819, a recombinant lipase for
the treatment of exocrine pancreatic insufficiency (EPI) in
patients with cystic fibrosis and chronic
pancreatitis.
James Sapirstein, CEO, AZRX states, “I am excited
to be a guest on the ‘New To The Street’ TV program. The show has
had a tremendous track record; I am happy to join the ranks. I look
forward to educating viewers about AzurRx BioPharma - about
our business, our biopharmaceutical products and therapies, and our
future to grow the Company.”
Vincent Caruso, CEO FMW Media Corp. and the
Creator / Producer of “New To The Street” TV states, “I am excited
to have AzurRx BioPharma, Inc. on the show for a 3-part series.
AZRX’s biopharmaceutical products and therapies make them a great
guest Company explaining their business to our syndicated TV
audiences.”
About
AzurRx BioPharma (NASDAQ:
AZRX):
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a
clinical stage biopharmaceutical company specializing in the
development of targeted, non-systemic therapies for
gastrointestinal (GI) diseases. The Company has a pipeline of three
gut-restricted GI clinical programs. The lead therapeutic candidate
is MS1819, a recombinant lipase for the
treatment of exocrine pancreatic insufficiency (EPI) in patients
with cystic fibrosis and chronic pancreatitis, currently in two
Phase 2 clinical trials. AzurRx is launching two clinical programs
using proprietary formulations of niclosamide, a pro-inflammatory
pathway inhibitor; FW-420, for grade 1 Immune
Checkpoint Inhibitor-associated colitis and diarrhea in oncology
patients and FW-1022, for COVID-19
gastrointestinal infections – https://azurrx.com.
About FMW Media: FMW Media
operates one of the longest-running U.S and international sponsored
and syndicated Nielsen Rated programming T.V. brands "New to the
Street," and its blockchain show "Exploring The Block." Since 2009,
these brands run biographical interview segment shows across major
U.S. television networks. The TV platforms reach over 540 million
homes both in the US and international markets. FMW recently added
Newsmax to its broadcasting platform with its first show
broadcasted Sunday, December 27th. The NEWSMAX New To The Street
show is syndicated on Sundays at 10 AM EST. FMW is also one of the
nation's largest buyers of linear television long and short form -
https://www.newsmaxtv.com/Shows/New-to-the-Street and
https://www.newtothestreet.com/
Forward-Looking Statements
Disclaimer: This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. In some cases, you can identify
forward-looking statements by the following words: "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "ongoing," "plan," "potential," "predict," "project,"
"should," "will," "would," or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. Forward-looking statements are not a guarantee
of future performance or results, and will not necessarily be
accurate indications of the times at, or by, which such performance
or results achieved. This press release should be considered in
light of all filings of the Company contained in the Edgar Archives
of the Securities and Exchange Commission at www.sec.gov.
FMW Media Contact: Bryan Johnson +1 (631) 766-7462
Bryan@NewToTheStreet.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/6101c2d5-4b3e-4579-81a6-180539dfbce1
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Apr 2023 to Apr 2024